Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin vs Amphotericin B in Neonates with Invasive Candidiasis
NCT01945281Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2014
- Primary completion
- Jan 2018
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of caspofungin in invasive candidiasis (2 arms), sponsored by Merck & Co. Primary endpoint: Percentage of Participants With Fungal-free Survival. Started Jan 2014; status: terminated.
02
Drugs
caspofungin
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on NCT01945281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01945281.